Bioneer A/S and ERS Genomics Limited announced today a non-exclusive license agreement to provide Bioneer with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents.

ERS Genomics holds the rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology.

State-of-the-art Gene Editing Core Facility

Bioneer will with the CRISPR/Cas9 license, strengthen the state-of-the-art gene editing core facility and capability to generate innovative, custom-designed cell lines. Bioener will continue the development of novel preclinical in vitro disease modelling platforms using gene editing technology combined with other in-house technologies, such as 3D bioprinting and advanced imaging.

“Bioneer has a long history of developing advanced cell-based disease models, and with this license agreement Bioneer’s gene editing proficiency will be further augmented. In other words, Bioneer will have the tools to take in vitro human cell models to the next level, by offering world-class disease modelling capabilities to support preclinical pharmaceutical development globally.”, says CSO Christian Clausen.

“With this license, we will expand our CRISPR-edited cell model portfolio, and continue to be an attractive R&D partner for the Danish and European life science community as well as for collaborators based in US and Asia.”, concludes CEO Lars H. Pedersen.

For more information, please contact Business Development Manager Lovisa M. Sunesson via email or call +45 45 160 444.

To read the full press release, please follow the link.

Share this post